Search company, investor...


Founded Year



Seed VC | IPO

Total Raised


Market Cap


Stock Price


About AngioGenex

AngioGenex (Ticker: AGGX) is a biopharmaceutical company committed to the discovery and development of Id protein inhibitors to address unmet medical needs in oncology and ophthalmology. AngioGenex’s lead development candidate is AGX-A, a novel small molecule being investigated for the treatment of cholangiocarcinoma (a form of liver cancer) and age-related macular degeneration (AMD). AngioGenex is headquartered in New York, NY.

Headquarters Location

425 Madison Avenue 48th Street 9th Floor Suite 902

New York, New York, 10017,

United States


Missing: AngioGenex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AngioGenex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

AngioGenex Patents

AngioGenex has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Transcription factors, Molecular biology, Tag editors, Metadata


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Transcription factors, Molecular biology, Tag editors, Metadata



Latest AngioGenex News

AngioGenex Co-Developping Anti-Cancer Drug with World Renowned Cancer Center

Feb 10, 2020

WITH WORLD RENOWNED CANCER CENTER AngioGenex, Inc. (AGGX.PK) ( ) announced an exclusive agreement with Memorial Sloan Kettering Cancer Center (MSK) to license and advance a series of anti-ID compounds through the regulatory process and into human clinical trials. The company has secured exclusive, worldwide rights to the commercial development of pharmacological treatments based on these molecules. “We are delighted that after decades of basic and translational research aimed at hitting these targets, we will finally be able to determine their benefit to patients” said the Company’s Scientific Advisory Board Chairman and MSK Member Dr. Robert Benezra. The scientific team, led by Dr. Benezra, has, in its recent in vitro and in vivo work identified a biological mechanism that allows certain fatal cancers of the liver, brain and breast to regenerate despite their apparent elimination by surgery, chemotherapy or radiation. Recent results indicate a fundamental mechanism, common to a significant group of cancers that allows these diseases to marshal a set of ID proteins which enable their persistent recurrence and lethality. The anti-ID molecules that AngioGenex is developing include their lead drug AGXA, described in a recent Cell Reports paper ( )31128-3.pdf), and a new manuscript available online in BioRxiv ( ). The drugs are intended to disrupt and ultimately disable the cellular pathways by which these intractable cancers repropagate. The initial clinical trials will be designed to focus on certain cancers of the liver, which, at present, invariably recur and are most often fatal. MSK and AngioGenex contemplate working together to prepare and file an Investigational New Drug (IND) application with the FDA. The company expects to begin the formal process of obtaining FDA approval of its IND application during the first half of 2020. It is the company’s intention to have its IND accepted by the FDA and to begin a Phase 1 clinical trial at MSK within a year of that initial meeting. Disclosures Researchers at MSK, including Dr. Robert Benezra, have intellectual property interests associated with the anti-ID compounds. Dr. Robert Benezra is also a co-founder of, holds equity interests in, and serves on the board of directors and on the scientific advisory board of AngioGenex. MSK has financial interests in AngioGenex through an agreement to license intellectual property to the company. About Angiogenex AngioGenex, Inc. is a New York based biopharmaceutical research and development company focused on a particular biological pathway common to certain lethal cancers and age related macular degeneration. For additional information, please visit our website at . This press release may contain forward-looking statements or predictions. These statements represent our judgment as of this date and are subject to risks and uncertainties that could materially affect the Company. AngioGenex undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Michael Strage

AngioGenex Frequently Asked Questions (FAQ)

  • When was AngioGenex founded?

    AngioGenex was founded in 1999.

  • Where is AngioGenex's headquarters?

    AngioGenex's headquarters is located at 425 Madison Avenue 48th Street, New York.

  • What is AngioGenex's latest funding round?

    AngioGenex's latest funding round is Seed VC.

  • How much did AngioGenex raise?

    AngioGenex raised a total of $870K.

  • Who are the investors of AngioGenex?

    Investors of AngioGenex include Atypical BioVentures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.